iX Biopharma Ltd. (SGX:42C)

Singapore · Delayed Price · Currency is SGD

0.5450

-0.0300 (-5.22%)

Sep 18, 2026, 5:10 PM SGT

Market Cap	593.60M +3,418.4%
Revenue (ttm)	6.85M -11.8%
Net Income	-7.99M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,829,000
Open	0.5800
Previous Close	0.5750
Day's Range	0.5450 - 0.5800
52-Week Range	0.0190 - 0.6250
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 10, 2026

About iX Biopharma

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, Australia and internationally. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, insomnia and other conditions.... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 2004

Employees 35

Stock Exchange Singapore Exchange

Ticker Symbol 42C

Full Company Profile

Financial Performance

In fiscal year 2026, iX Biopharma's revenue was 6.85 million, a decrease of -11.77% compared to the previous year's 7.77 million. Losses were -7.99 million, -21.18% less than in 2025.

Financial Statements